{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:08:47Z","timestamp":1782972527187,"version":"3.54.5"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["1OT2OD026580-01"],"award-info":[{"award-number":["1OT2OD026580-01"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["16PRE27260295"],"award-info":[{"award-number":["16PRE27260295"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["R01HL128537"],"award-info":[{"award-number":["R01HL128537"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19CDA34770101"],"award-info":[{"award-number":["19CDA34770101"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["2R01HL128537"],"award-info":[{"award-number":["2R01HL128537"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["5U01HL126273"],"award-info":[{"award-number":["5U01HL126273"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.yjmcc.2021.05.015","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T19:54:18Z","timestamp":1622318058000},"page":"163-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline"],"prefix":"10.1016","volume":"158","author":[{"given":"Kevin R.","family":"DeMarco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuharu","family":"Furutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.D.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Tsuen","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slava","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van A.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei Y.","family":"Noskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Yarov-Yarovoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Sack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen E.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Vorobyov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/2229-516X.112233","article-title":"A review of drug isomerism and its significance","volume":"3","author":"Chhabra","year":"2013","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1570163816666190502101803","article-title":"Drug stereochemistry: a prodigy for pharmacology and drug development","volume":"17","author":"Gandhi","year":"2020","journal-title":"Current Drug Discovery Technol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfp097","article-title":"Chiral toxicology: it\u2019s the same thing\u2026 only different","volume":"110","author":"Smith","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0020","first-page":"137","article-title":"Stereoselective inhibition of the hERG1 potassium channel","volume":"1","author":"Sintra Grilo","year":"2010","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0025","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.05.015_bb0030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","article-title":"Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval","volume":"170","author":"Ansermot","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.05.015_bb0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","article-title":"Cardiotoxicity of antimalarial drugs","volume":"7","author":"White","year":"2007","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.yjmcc.2021.05.015_bb0040","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3390\/ijms17101648","article-title":"Stereoselective blockage of quinidine and quinine in the hERG channel and the effect of their rescue potency on drug-induced hERG trafficking defect","volume":"17","author":"Yan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1399-6576.1995.tb04316.x","article-title":"Isomerism and anaesthetic drugs","volume":"39","author":"Calvey","year":"1995","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.05.015_bb0050","first-page":"1427","article-title":"Differences in cardiotoxicity of bupivacaine and ropivacaine are the result of physicochemical and stereoselective properties","volume":"96","author":"Graf","year":"2002","journal-title":"Anesthesiol. J. Am. Soc. Anesthesiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0055","first-page":"496","article-title":"Is comparative cardiotoxicity of S (\u2212) and R(+) bupivacaine related to enantiomer-selective inhibition of L-type Ca2+ channels?","volume":"92","author":"Zapata-Sudo","year":"2001","journal-title":"Anesth. Analg."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.05.015_bb0060","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bjp.0704978","article-title":"Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block","volume":"137","author":"Gonz\u00e1lez","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0065","first-page":"102","article-title":"Local anesthetic interaction with human ether-a-go-go\u2013related gene (HERG) ChannelsRole of aromatic amino acids Y652 and F656","volume":"103","author":"Siebrands","year":"2005","journal-title":"Anesthesiol. J. Am. Soc. Anesthesiol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0070","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/annonc\/4.suppl_2.S7","article-title":"Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing","volume":"4","author":"Wainer","year":"1993","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","article-title":"Chiral drugs: an overview","volume":"2","author":"Nguyen","year":"2006","journal-title":"Int. J. Biomed. Sci."},{"issue":"15","key":"10.1016\/j.yjmcc.2021.05.015_bb0080","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0002-9149(99)80717-6","article-title":"Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial)","volume":"75","author":"Waldo","year":"1995","journal-title":"Am. J. Cardiol."},{"issue":"9019","key":"10.1016\/j.yjmcc.2021.05.015_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0090","first-page":"346","article-title":"Clinical experience with sotalol in the treatment of cardiac arrhythmias","volume":"16","author":"Kirschenbaum","year":"1994","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJM199407073310108","article-title":"Sotalol","volume":"331","author":"Hohnloser","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0735-1097(97)00190-3","article-title":"Efficacy and safety of d, l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest","volume":"30","author":"Haverkamp","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00005344-199703000-00011","article-title":"Efficacy and proarrhythmia with the use of d, l-sotalol for sustained ventricular tachyarrhythmias","volume":"29","author":"K\u00fchlkamp","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0735-1097(98)00521-X","article-title":"Suppression of sustained ventricular tachyarrhythmias: a comparison of d, l-sotalol with no antiarrhythmic drug treatment","volume":"33","author":"K\u00fchlkamp","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.yjmcc.2021.05.015_bb0115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","article-title":"Prevention of implantable-defibrillator shocks by treatment with sotalol","volume":"340","author":"Pacifico","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0002-8703(99)70484-9","article-title":"Sotalol: an important new antiarrhythmic","volume":"137","author":"Anderson","year":"1999","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/107424849900400108","article-title":"Sotalol: current status and expanding indications","volume":"4","author":"Singh","year":"1999","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0130","series-title":"Highlights Of Prescribing Information: Sotalol hydrochloride injection for intravenous use U.S. Food and Drug Administration Silver Spring, MD, U.S.A","year":"2009"},{"issue":"9","key":"10.1016\/j.yjmcc.2021.05.015_bb0135","doi-asserted-by":"crossref","first-page":"875. e1","DOI":"10.1016\/j.amjmed.2011.04.025","article-title":"The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis","volume":"124","author":"Kerin","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0140","series-title":"Therapeutic Use and Major Side Effects of Sotalol","author":"Giardina","year":"2018"},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0145","series-title":"Hydrochloride, Drugs.com","author":"Sotalol","year":"2018"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0002-9149(90)90207-H","article-title":"Clinical safety profile of sotalol in patients with arrhythmias","volume":"65","author":"Soyka","year":"1990","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7326\/0003-4819-117-2-141","article-title":"Proarrhythmia in patients treated for atrial fibrillation or flutter","volume":"117","author":"Falk","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.05.015_bb0160","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1016\/0002-9149(93)90024-7","article-title":"Clinical safety profile of sotalol in the treatment of arrhythmias","volume":"72","author":"MacNeil","year":"1993","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.yjmcc.2021.05.015_bb0165","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1161\/01.CIR.94.10.2535","article-title":"Sex difference in risk of torsade de pointes with d, l-sotalol","volume":"94","author":"Lehmann","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"suppl_4","key":"10.1016\/j.yjmcc.2021.05.015_bb0175","first-page":"iv37","article-title":"Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias","volume":"9","author":"Shantsila","year":"2007","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0735-1097(86)80268-6","article-title":"Electrophysiologic effects of the levo-and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics","volume":"7","author":"Kato","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2\u20133","key":"10.1016\/j.yjmcc.2021.05.015_bb0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(86)90597-2","article-title":"Comparative \u03b2-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs","volume":"132","author":"Gomoll","year":"1986","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2125.1990.tb03765.x","article-title":"A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism","volume":"30","author":"Funck-Brentano","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"suppl_H","key":"10.1016\/j.yjmcc.2021.05.015_bb0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/14.suppl_H.24","article-title":"Electrophysiologic properties of sotalol and d-sotalol. A current view","volume":"14","author":"Touboul","year":"1993","journal-title":"Eur. Heart J."},{"issue":"suppl_H","key":"10.1016\/j.yjmcc.2021.05.015_bb0200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/eurheartj\/14.suppl_H.30","article-title":"Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d, l-sotalol","volume":"14","author":"Funck-Brentano","year":"1993","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehs351","article-title":"Drug-induced arrhythmia: pharmacogenomic prescribing?","volume":"34","author":"Behr","year":"2013","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002280050714","article-title":"QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience","volume":"56","author":"De Ponti","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0215","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.pharmthera.2013.03.005","article-title":"Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity","volume":"138","author":"Ferri","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.05.015_bb0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1056\/NEJM198908103210608","article-title":"The cardiac arrhythmia suppression trial (CAST)","volume":"321","author":"Ruskin","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel","volume":"81","author":"Sanguinetti","year":"1995","journal-title":"Cell"},{"issue":"5220","key":"10.1016\/j.yjmcc.2021.05.015_bb0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.7604285","article-title":"HERG, a human inward rectifier in the voltage-gated potassium channel family","volume":"269","author":"Trudeau","year":"1995","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0240","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K(+) channels: structure, function, and clinical significance","volume":"92","author":"Vandenberg","year":"2012","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.yjmcc.2021.05.015_bb0245","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7083","key":"10.1016\/j.yjmcc.2021.05.015_bb0250","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0255","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium","volume":"167","author":"Sager","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0260","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.yjmcc.2014.02.018","article-title":"In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome","volume":"72","author":"Romero","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro Proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J. Biomol. Screen."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0275","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1039\/C6MB00814C","article-title":"Stereoselective binding of agonists to the \u03b2 2-adrenergic receptor: insights into molecular details and thermodynamics from molecular dynamics simulations","volume":"13","author":"Plazinska","year":"2017","journal-title":"Mol. BioSyst."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.05.015_bb0280","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/aps.2013.78","article-title":"Stereoselective binding of chiral drugs to plasma proteins","volume":"34","author":"Shen","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"98","key":"10.1016\/j.yjmcc.2021.05.015_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002588","article-title":"A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms","volume":"3","author":"Moreno","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.05.015_bb0290","first-page":"H766","article-title":"Computational approaches to understand cardiac electrophysiology and arrhythmias","volume":"303","author":"Roberts","year":"2012","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.05.015_bb0295","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s10439-016-1628-0","article-title":"Multi-scale modeling of the cardiovascular system: disease development, progression, and clinical intervention","volume":"44","author":"Zhang","year":"2016","journal-title":"Ann. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.05.015_bb0300","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s10439-016-1563-0","article-title":"Multiscale modeling in the clinic: drug design and development","volume":"44","author":"Clancy","year":"2016","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0305","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/CIRCRESAHA.119.316404","article-title":"A computational pipeline to predict Cardiotoxicity:from the atom to the rhythm","volume":"126","author":"Yang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0310","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fphar.2018.00026","article-title":"Digging into lipid membrane permeation for cardiac Ion Channel blocker d-Sotalol with all-atom simulations","volume":"9","author":"DeMarco","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0315","article-title":"Atomistic modeling towards predictive cardiotoxicity","author":"DeMarco","year":"2019","journal-title":"BioRxiv"},{"issue":"6","key":"10.1016\/j.yjmcc.2021.05.015_bb0320","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1073\/pnas.1909196117","article-title":"Selectivity filter modalities and rapid inactivation of the hERG1 channel","volume":"117","author":"Miranda","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0325","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2017.03.048","article-title":"Cryo-EM Structure of the Open Human Ether-a-go-go-Related K+ Channel hERG","volume":"169","author":"Wang","year":"2017","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.yjmcc.2021.05.015_bb0330","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.RES.87.11.1012","article-title":"Probing the interaction between inactivation gating and Dd-sotalol block of HERG","volume":"87","author":"Numaguchi","year":"2000","journal-title":"Circ. Res."},{"issue":"45","key":"10.1016\/j.yjmcc.2021.05.015_bb0335","doi-asserted-by":"crossref","first-page":"17656","DOI":"10.1073\/pnas.0702626104","article-title":"Prediction of the structure of symmetrical protein assemblies","volume":"104","author":"Andre","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"40","key":"10.1016\/j.yjmcc.2021.05.015_bb0340","doi-asserted-by":"crossref","first-page":"15682","DOI":"10.1073\/pnas.0702515104","article-title":"Toward high-resolution prediction and design of transmembrane helical protein structures","volume":"104","author":"Barth","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.05.015_bb0345","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/prot.20817","article-title":"Multipass membrane protein structure prediction using Rosetta","volume":"62","author":"Yarov-Yarovoy","year":"2006","journal-title":"Proteins"},{"issue":"25","key":"10.1016\/j.yjmcc.2021.05.015_bb0350","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data","volume":"34","author":"Huang","year":"2013","journal-title":"J. Comput. Chem."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.05.015_bb0355","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1021\/ct300400x","article-title":"Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone \u03d5, \u03c8 and side-chain \u03c71 and \u03c72 dihedral angles","volume":"8","author":"Best","year":"2012","journal-title":"J. Chem. Theory Comput."},{"issue":"23","key":"10.1016\/j.yjmcc.2021.05.015_bb0360","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1021\/jp101759q","article-title":"Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types","volume":"114","author":"Klauda","year":"2010","journal-title":"J. Phys. Chem. B"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0365","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.05.015_bb0370","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.yjmcc.2021.05.015_bb0375","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0380","first-page":"41","article-title":"Anton 2: Raising the bar for performance and programmability in a special-purpose molecular dynamics supercomputer","author":"Shaw","year":"2014","journal-title":"Int Conf High Perfor"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0385","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0021-9991(77)90121-8","article-title":"Nonphysical sampling distributions in Monte Carlo free-energy estimation: umbrella sampling","volume":"23","author":"Torrie","year":"1977","journal-title":"J. Comput. Phys."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.05.015_bb0390","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1021\/ct300468g","article-title":"Calculation of free energy landscape in multi-dimensions with Hamiltonian-exchange umbrella sampling on petascale supercomputer","volume":"8","author":"Jiang","year":"2012","journal-title":"J. Chem. Theory Comput."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0395","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1124\/mol.108.049056","article-title":"Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels","volume":"74","author":"Perrin","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.05.015_bb0400","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.RES.77.4.718","article-title":"High- and low-affinity sites for [3H]dofetilide binding to Guinea pig myocytes","volume":"77","author":"Duff","year":"1995","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0405","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0410","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1161\/01.CIR.83.2.536","article-title":"Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans","volume":"83","author":"Funck-Brentano","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0415","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A short history of SHELX","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Crystallographica, Section A"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0420","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophys. J."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0425","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","article-title":"Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches","volume":"391","author":"Hamill","year":"1981","journal-title":"Pflugers Arch."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0430","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0026-895X(24)23209-0","article-title":"Molecular determinant of high-affinity dofetilide binding toHERG1 expressed in Xenopus oocytes: involvement of S6 sites","volume":"57","author":"Lees-Miller","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"22","key":"10.1016\/j.yjmcc.2021.05.015_bb0435","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome","volume":"97","author":"Mitcheson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.yjmcc.2021.05.015_bb0440","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1113\/jphysiol.2010.194670","article-title":"Symposium review: revealing the structural basis of action of hERG potassium channel activators and blockers","volume":"588","author":"Perry","year":"2010","journal-title":"J. Physiol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0445","series-title":"An Update on the Structure of hERG, Frontiers in Pharmacology 10","author":"Butler","year":"2019"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0450","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acs.jcim.9b00773","article-title":"Revealing molecular determinants of hERG blocker and activator binding","volume":"60","author":"Dickson","year":"2019","journal-title":"J. Chem. Inf. Model."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.05.015_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003090","article-title":"Exploring volatile general anesthetic binding to a closed membrane-bound bacterial voltage-gated sodium channel via computation","volume":"9","author":"Raju","year":"2013","journal-title":"PLoS Comput. Biol."},{"issue":"36","key":"10.1016\/j.yjmcc.2021.05.015_bb0460","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.1408710111","article-title":"Local anesthetic and antiepileptic drug access and binding to a bacterial voltage-gated sodium channel","volume":"111","author":"Boiteux","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.05.015_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003688","article-title":"Locating the route of entry and binding sites of benzocaine and phenytoin in a bacterial voltage gated sodium channel","volume":"10","author":"Martin","year":"2014","journal-title":"PLoS Comput. Biol."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.05.015_bb0470","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1073\/pnas.1817446116","article-title":"Structural basis for antiarrhythmic drug interactions with the human cardiac sodium channel","volume":"116","author":"Nguyen","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0475","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/mol.118.115642","article-title":"The pore-lipid interface: role of amino-acid determinants of lipophilic access by ivabradine to the hERG1 pore domain","volume":"96","author":"Perissinotti","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0480","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3389\/fphar.2020.00914","article-title":"Allosteric coupling between drug binding and the aromatic cassette in the pore domain of the hERG1 channel: implications for a state-dependent blockade","volume":"11","author":"Kudaibergenova","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0485","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bph.12967","article-title":"Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors","volume":"172","author":"Yu","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0490","first-page":"130","article-title":"The basis for low-affinity herg potassium channel block by sotalol","volume":"8","author":"Zhang","year":"2017","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-53120-6","article-title":"Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs","volume":"9","author":"Negami","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.05.015_bb0500","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Die Pharmazie An Int. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0505","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pbiomolbio.2011.06.004","article-title":"Multi-scale modeling in biology: how to bridge the gaps between scales?","volume":"107","author":"Qu","year":"2011","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-bioeng-071811-150104","article-title":"Multiscale computational models of complex biological systems","volume":"15","author":"Walpole","year":"2013","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ddmod.2014.04.001","article-title":"Computational models for predictive cardiac ion channel pharmacology","volume":"14","author":"Yarov-Yarovoy","year":"2014","journal-title":"Drug Discov. Today Dis. Model."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0520","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1113\/JP271282","article-title":"In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia","volume":"594","author":"Yang","year":"2016","journal-title":"J. Physiol."},{"issue":"14","key":"10.1016\/j.yjmcc.2021.05.015_bb0525","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1113\/JP273142","article-title":"A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias","volume":"595","author":"Yang","year":"2017","journal-title":"J. Physiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0530","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0735-1097(98)90070-5","article-title":"Cellular electrophysiologic responses of isolated neonatal and adult cardiac fibers to d-sotalol","volume":"11","author":"Yabek","year":"1988","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0535","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2165\/00003495-199549050-00003","article-title":"Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol","volume":"49","author":"Advani","year":"1995","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.05.015_bb0540","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/0002-9149(93)90020-D","article-title":"Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents","volume":"72","author":"Singh","year":"1993","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0545","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1253\/circj.CJ-08-0540","article-title":"l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts","volume":"73","author":"Hsieh","year":"2009","journal-title":"Circulation J."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0550","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000016304","article-title":"Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes","volume":"9","author":"Waldegger","year":"1999","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0555","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0022-3565(24)39158-X","article-title":"Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels","volume":"294","author":"Yang","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0560","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0022-3565(25)20919-3","article-title":"Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers","volume":"232","author":"Carmeliet","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0565","series-title":"Naunyn-Schmiedeberg's Archives of Pharmacology","first-page":"215","article-title":"(+)-Sotalol causes significant occupation of \u03b2-adrenoceptors at concentrations that prolong cardiac repolarization","volume":"341(3)","author":"Reid","year":"1990"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0570","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/01.CIR.91.2.262","article-title":"\u03b2-Adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol","volume":"91","author":"Groh","year":"1995","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.yjmcc.2021.05.015_bb0575","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1111\/bph.13558","article-title":"Pharmacokinetic\u2013pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-\u00e0-go-go-related gene binding and functional inhibition assays and conscious dog studies","volume":"173","author":"Dubois","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0580","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2009.04.198","article-title":"Effect of compound plate composition on measurement of hERG current IC50 using PatchXpress","volume":"60","author":"Mo","year":"2009","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep02100","article-title":"MICE models: superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0590","doi-asserted-by":"crossref","first-page":"114961","DOI":"10.1016\/j.taap.2020.114961","article-title":"A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm","author":"Ridder","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0595","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2b","key":"10.1016\/j.yjmcc.2021.05.015_bb0600","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1476-5381.2011.01378.x","article-title":"hERG subunit composition determines differential drug sensitivity","volume":"164","author":"Abi-Gerges","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0605","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1476-5381.2009.00334.x","article-title":"Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel","volume":"159","author":"M\u00e4nnikk\u00f6","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0610","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0615","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/toxsci\/kfy299","article-title":"Evaluation of possible Proarrhythmic potency: comparison of the effect of Dofetilide Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and native I Kr currents and on cardiac action potential","volume":"168","author":"Orvos","year":"2019","journal-title":"Toxicol. Sci."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.05.015_bb0620","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1046\/j.1540-8167.2004.04099.x","article-title":"Comparative pharmacology of Guinea pig cardiac myocyte and cloned hERG (IKr) channel","volume":"15","author":"Davie","year":"2004","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.05.015_bb0625","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10439-009-9690-5","article-title":"Identification of I Kr kinetics and drug binding in native myocytes","volume":"37","author":"Zhou","year":"2009","journal-title":"Ann. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0630","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1006\/jmcc.1996.0100","article-title":"[3H] Dofetilide binding: biological models that manifest solely the high or the low affinity binding site","volume":"28","author":"Fiset","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.05.015_bb0635","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4236\/jbise.2017.1011040","article-title":"Cardiomyocytes derived from human induced pluripotent stem cells: An in-vitro model to predict cardiac effects of drugs","volume":"10","author":"Sube","year":"2017","journal-title":"J. Biomed. Sci. Eng."},{"issue":"21","key":"10.1016\/j.yjmcc.2021.05.015_bb0640","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1111\/bph.13577","article-title":"Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?","volume":"174","author":"Sala","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0645","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/cells8050403","article-title":"Current challenges of iPSC-based disease modeling and therapeutic implications","volume":"8","author":"Doss","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0650","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fphys.2018.00207","article-title":"Determinants of isoform-specific gating kinetics of hERG1 channel: combined experimental and simulation study","volume":"9","author":"Perissinotti","year":"2018","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0655","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(00)80728-X","article-title":"MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia","volume":"97","author":"Abbott","year":"1999","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0660","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.vascn.2014.07.002","article-title":"Prediction of thorough QT study results using action potential simulations based on ion channel screens","volume":"70","author":"Mirams","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.05.015_bb0665","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpt.367","article-title":"Improved prediction of drug-induced Torsades de pointes through simulations of dynamics and machine learning algorithms","volume":"100","author":"Lancaster","year":"2016","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0670","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fphys.2017.00597","article-title":"Quantitative comparison of effects of dofetilide, sotalol, quinidine, and verapamil between human ex vivo trabeculae and in silico ventricular models incorporating inter-individual action potential variability","volume":"8","author":"Britton","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0675","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.05.015_bb0680","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.yjmcc.2009.09.019","article-title":"A novel computational model of the human ventricular action potential and Ca transient","volume":"48","author":"Grandi","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0685","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48890","article-title":"Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block","volume":"8","author":"Tomek","year":"2019","journal-title":"Elife"},{"issue":"23","key":"10.1016\/j.yjmcc.2021.05.015_bb0690","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1088\/0031-9155\/51\/23\/014","article-title":"Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions","volume":"51","author":"Ten Tusscher","year":"2006","journal-title":"Phys. Med. Biol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.05.015_bb0695","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.str.2020.12.007","article-title":"Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole","volume":"29","author":"Asai","year":"2021","journal-title":"Structure"},{"issue":"5","key":"10.1016\/j.yjmcc.2021.05.015_bb0700","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd6203","article-title":"Mechanism of C-type inactivation in the hERG potassium channel","volume":"7","author":"Li","year":"2021","journal-title":"Sci. Adv."},{"issue":"7303","key":"10.1016\/j.yjmcc.2021.05.015_bb0705","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature09153","article-title":"Structural mechanism of C-type inactivation in K+ channels","volume":"466","author":"Cuello","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0710","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28032","article-title":"The gating cycle of a K+ channel at atomic resolution","volume":"6","author":"Cuello","year":"2017","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.yjmcc.2021.05.015_bb0715","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nsmb.3457","article-title":"Crystal structure of an inactivated mutant mammalian voltage-gated K+ channel","volume":"24","author":"Pau","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0720","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37558","article-title":"Single-particle cryo-EM structure of a voltage-activated potassium channel in lipid nanodiscs","volume":"7","author":"Matthies","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.yjmcc.2021.05.015_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41422-019-0249-1","article-title":"Binding pathway determines norepinephrine selectivity for the human \u03b2 1 AR over \u03b2 2 AR","author":"Xu","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.05.015_bb0730","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/mol.113.090951","article-title":"Modeling the effects of \u03b21-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling","volume":"86","author":"Amanfu","year":"2014","journal-title":"Mol. Pharmacol."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282821001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282821001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:22:15Z","timestamp":1777418535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282821001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":146,"alternative-id":["S0022282821001097"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2021.05.015","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2021.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}